United Therapeutics Corp
UTHR
Market Cap$13.6B
Close$
$875.47
184.2% upside
Current Fair Value
184.2% upsideUndervalued by 184.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $13.60 Billion |
|---|---|
| Enterprise Value | $11.90 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $26.44 |
| Beta | 0.58 |
| Outstanding Shares | 44,900,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 11.18 |
|---|---|
| PEG | 219.7 |
| Price to Sales | 4.67 |
| Price to Book Ratio | 2.04 |
| Enterprise Value to Revenue | 3.97 |
| Enterprise Value to EBIT | 7.72 |
| Enterprise Value to Net Income | 9 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About United Therapeutics Corp
920 employees
CEO: Martine Rothblatt United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power o...